Pacritinib receives priority review for myelofibrosis with severe thrombocytopenia
Click Here to Manage Email Alerts
The FDA granted priority review to pacritinib for treatment of patients with myelofibrosis with severe thrombocytopenia, according to the agent’s manufacturer.
Approximately one-third of patients with myelofibrosis develop severe thrombocytopenia, defined as blood platelet counts less than 50 x 109/L.
Treatment options for these patients are limited, and OS is approximately 15 months.
Thrombocytopenia is associated with underlying disease; however, it also can result from treatment with ruxolitinib (Jakafi, Incyte), a Janus kinase inhibitor approved for myelofibrosis. This can lead to treatment discontinuation. Survival for patients who discontinue ruxolitinib averages 7 to 14 months.
Pacritinib (CTI BioPharma) is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1 and CSF1R.
The FDA accepted a new drug application for the agent based on results of the phase 3 PERSIST-2 and PERSIST-1 trials, as well as the phase 2 PAC203 trial.
Patients with myelofibrosis and severe thrombocytopenia enrolled in these studies received 200 mg pacritinib twice daily.
In the PERSIST-2 study, a higher percentage of patients who received pacritinib than best available therapy achieved at least 35% reduction in spleen volume (29% vs. 3%) and at least a 50% reduction in total symptom scores (23% vs. 13%).
Adverse events among pacritinib-treated patients generally were low grade, manageable with supportive care and rarely led to treatment discontinuation, according to a CTI BioPharma-issued press release. Researchers also reported stabilized platelet counts and hemoglobin levels among pacritinib-treated patients.
The FDA is expected to make a decision on the application by Nov. 30.
“We are pleased that the FDA's acceptance of our NDA brings us one step closer to our goal of providing [patients with myelofibrosis] with severe thrombocytopenia a new treatment option,” Adam R. Craig, MD, PhD, president and CEO of CTI BioPharma, said in the release. “With commercial preparation underway, we believe we will be well-positioned for a potential U.S. launch later this year. We look forward to working with the FDA during its review of our application.”
Read more about
Click Here to Manage Email Alerts